MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

JSH-150

CAS No. : 2247481-21-4

MCE 站：JSH-150

产品活性：JSH-150 是一种高效的选择性 CDK9 抑制剂， IC₅₀ 为 1 nM。

研究领域：Cell Cycle/DNA Damage

作用靶点：CDK

In Vitro: The antiproliferative effect of JSH-150 is examined ton a panel of established cancer cell lines. JSH-150 exhibits potent antiproliferative activities in solid tumor cell lines such as A375 (melanoma), A431 (squamous), BE(2)M17 (neuroblastoma), GIST-T1 (GIST) and COLO205 (colon cancer) with GI₅₀ values from 0.002 to 0.044 ?M. In the leukemia cell lines including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and B cell lymphoma cell lines, JSH-150 also displays strong growth inhibition efficacies with GI₅₀s ranging from single to double digit nM. In addition, JSH-150 is much less sensitive in normal CHO cells (GI₅₀: 1.1 ?M) compared with the cancer cell lines.

In Vivo: Treatment of JSH-150 at all dosages, i.e., 10, 20 and 30 mg/kg/day, can almost completely suppress the tumor progression in the first two weeks and does not affect the animal’s weight indicating that there is no general cytotoxicity at these doses. After stopping the treatment of JSH-150, the tumors of the animals treated with 10 mpk drug dosage start to grow again. However, this tumor recurrence is not observed in the 20 and 30 mpk dosage groups during the following week after administration of JSH-150 is stopped and p values are quantified on the 21st day, which are 0.042, 0.0035 and 0.0028, respectively. The PK properties of JSH-150 are evaluated in different species including mice, Sprague-Dawley rats and beagle dogs through intravenous injection and oral administration. JSH-150 is absorbed rapidly in dogs and mice (T_max=1.33 h and 2.00 h respectively) but slowly in rats (T_max=3.33 h). JSH-150 also displays different half-lives in three different species via oral administration (T_1/2=1.55 h in mice, 3.37 h in rats and 20.37 h in dogs), which indicates that it is metabolized very slowly in dogs compared with mice and rats. In addition, JSH-150 exhibits acceptable bioavailability in mice, rats and dogs (F=45.01%, 45.10% and 39.15%, respectively). The PK properties indicated that JSH-150 is suitable for oral administration.

相关产品：Palbociclib  |  Abemaciclib methanesulfonate  |  THZ531  |  Ribociclib  |  Dinaciclib  |  THZ1  |  Flavopiridol  |  Seliciclib  |  Ro-3306  |  AZD4573  |  NVP-2  |  PF-06873600  |  CYC065  |  SNS-032  |  Samuraciclib hydrochloride  |  SB1317  |  AT7519  |  SR-4835  |  AZD-5438  |  Simurosertib  |  AUZ 454  |  CCT-251921  |  GSK 3 Inhibitor IX  |  JNJ-7706621  |  OTS964 hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。